Letter to the Editors
Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target
Yonatan Kok,
Corresponding Author
Yonatan Kok
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Search for more papers by this author Jenny Nicolopoulos,
Jenny Nicolopoulos
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this author George Varigos,
George Varigos
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this author Anne Howard,
Anne Howard
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Dermatology, The Western Hospital, Footscray, Victoria, Australia
Search for more papers by this author Con Dolianitis,
Con Dolianitis
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this author
Yonatan Kok,
Corresponding Author
Yonatan Kok
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Search for more papers by this author Jenny Nicolopoulos,
Jenny Nicolopoulos
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this author George Varigos,
George Varigos
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this author Anne Howard,
Anne Howard
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Dermatology, The Western Hospital, Footscray, Victoria, Australia
Search for more papers by this author Con Dolianitis,
Con Dolianitis
Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
Search for more papers by this author
First published: 13 April 2020
No abstract is available for this article.
References
- 1Braun-Falco M, Kovnerystyy O, Lohse P et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)–a new autoinflammatory syndrome distinct from PAPA syndrome. J. Am. Acad. Dermatol. 2012; 66: 409–15.
- 2Murphy B, Morrison G, Podmore P. Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis. Int. J. Colorectal. Dis. 2015; 30: 1139–40.
- 3Yang EJ, Beck KM, Liao W. Tildrakizumab-asmn: What’s in a Name? Am. J. Clin. Dermatol. 2018; 19: 291–2.
